Drug Database
IN

indometacin (IV) (Indocin IV)

✓ Approved

Merck & Co. · PTGS1 · 小分子

什么是 indometacin (IV)?

indometacin (IV) 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Indocin IV
公司Merck & Co.
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

indometacin (IV) 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

indometacin (IV) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersPatent ductus arteriosus✓ Approved

相关研究文献

PubMedBMC cancer2026-11-19

Five-year survival and prognostic factors of cervical cancer (stages I-IV) in Rwanda: a population-based analysis, 2017-2021.

Ange Iradukunda I, Gbadamosi Mojeed Akorede MA

Cervical cancer remains a leading cause of cancer-related mortality among women in low- and middle-income countries. This study assessed five-year survival and prognostic factors among patients diagnosed with cervical cancer in Rwanda. We conducted a population-based retrospective cohort study using data from the Rwanda National Cancer Registry, including patients diagnosed with cervical cancer (Stages I-IV) between 2017 and 2021. Survival probabilities were estimated using the Kaplan-Meier method, and prognostic factors were identified using Cox proportional hazards models. A total of 1,075 patients were included. The mean age at diagnosis was 54.1 years (SD 12.7). FIGO stage distribution at diagnosis was as follows: Stage I (9.0%), Stage II (18.7%), Stage III (32.0%), Stage IV (10.5%), and unknown stage (29.8%). During follow-up, 20.0% of patients died, while 77.7% were censored. An advanced stage at diagnosis was significantly associated with increased mortality (Stage IV vs. Stage I: aHR = 3.84, 95% CI: 1.98-7.45; p < 0.001). In sensitivity analyses, including a worst-case scenario in which the missing stage was classified as Stage IV, the association between advanced stage and mortality remained robust (Stage IV vs. Stage I: aHR = 2.43, 95% CI: 1.26-4.70; p = 0.008). Survival among cervical cancer patients in Rwanda remains strongly associated with stage at diagnosis. The high proportion of advanced-stage disease and missing stage data underscores the need for improved early detection, data completeness, and follow-up systems.

PMID 43052865
阅读全文 →
PubMedBMC women's health2026-11-19

Diagnostic performance of RMI I-IV for pelvic/adnexal masses after hysterectomy: a retrospective single-center study.

Zhou Meng M, Wang Ming M, Xin Le L

To evaluate and compare the diagnostic performance of four Risk of Malignancy Index (RMI) models (I-IV) in differentiating benign from malignant pelvic masses newly developed in post-hysterectomy patients. This 10-year retrospective single-center study enrolled 171 patients with newly developed pelvic/adnexal masses after hysterectomy who received surgical resection and pathological diagnosis. Baseline clinical and imaging parameters-including age, CA125 level, tumor size, ultrasound features, and menopausal status-were collected. Receiver operating characteristic (ROC) curves and DeLong's test were used to compare the area under the curve (AUC) of RMI I-IV, while the Youden index was used to determine the optimal cutoff for each model. Diagnostic sensitivity, specificity, and accuracy were calculated using both traditional published thresholds and cohort-specific optimal cutoffs. Numerically, RMI I exhibited the highest specificity (98.6%) and the largest AUC value (0.973, 95% CI: 0.942-1.000) among the four evaluated indices. Overall, all RMI models demonstrated good diagnostic performance. At a cutoff of ≥ 60, RMI I achieved a sensitivity of 96.7% and a specificity of 91.5%. In pairwise DeLong's tests, the AUC of RMI I was significantly higher than that of RMI II and RMI IV (p = 0.009 and 0.013, respectively), while its advantage over RMI III did not reach statistical significance (p = 0.057). Importantly, however, none of the RMI models yielded satisfactory sensitivity for detecting FIGO stage I-II epithelial ovarian cancers. Among the four models, RMI I demonstrated superior preoperative risk stratification value for post-hysterectomy pelvic masses. Nevertheless, the present study is subject to several limitations, including its single-center retrospective design, inherent surgical selection bias, and a relatively small sample with only 30 malignant cases. Moreover, the optimal thresholds derived from this cohort are exploratory and should not be generalized to routine clinical practice without external multi-center validation. As such, RMI should be regarded as an auxiliary assessment tool rather than the sole basis for clinical decision-making.

PMID 43052960
阅读全文 →
PubMedBMC medical informatics and decision making2026-11-19

Using explainable machine learning for early detection of diabetic kidney disease in Rwandan diabetic patients.

Majyambere Silas S, Lindgren Tony T, Twizere Celestin C, Rugero Fiacre Rugamba FR

The global prevalence of diabetes is increasing, often leading to complications such as diabetic kidney disease (DKD). Uncontrolled blood glucose and hypertension are key risk factors that progressively impair kidney function, potentially resulting in kidney failure or end-stage renal disease (ESRD). Early detection of DKD is crucial but challenging due to its asymptomatic onset. This study employs explainable artificial intelligence (XAI) to predict DKD risk in diabetic patients using tree-based ensemble models and Shapley Additive exPlanations (SHAP), leveraging the Medical Information Mart for Intensive Care (MIMIC)-IV dataset and a dataset from hospitals in Rwanda. Among the models used, Random Forest demonstrated superior performance, achieving accuracies of 87.97% on MIMIC-IV and 91.70% on the Rwandan dataset. XGBoost outperformed other models, achieving 79.32% accuracy when trained on the Rwanda dataset and evaluated on the MIMIC-IV dataset. Models were evaluated using multiple metrics, including ROC-AUC and calibration curves. SHAP provided both global and individual-level explanations, with predictions validated using estimated glomerular filtration rate (eGFR) values. Our findings highlight the potential of combining predictive modeling with explainability to support transparent and trustworthy early detection of DKD in clinical practice. Compared with the current eGFR-based risk assessment, this approach incorporates additional predictors that improve risk identification. Blood urea nitrogen (Urea), Hemoglobin, Total cholesterol (TC), Blood glucose (BG), and Creatinine are the leading predictors of DKD risk. This study suggests that the XAI model can be used to assess DKD risk, while eGFR remains valuable for confirming the diagnosis and disease stage.

PMID 43053061
阅读全文 →
PubMedJournal of prosthodontics : official journal of the American College of Prosthodontists2026-11-19

Basic concepts of rotational path removable partial denture: A narrative review and case report.

Sones Amerian D AD, Kienzle Kason K, Batagower Jordan J, Bergamini Marco M et al.

The rotational path removable partial denture (RPRPD) design is a viable treatment approach for the esthetic and functional rehabilitation of Kennedy's Classification III and IV partially edentulous patients. The purpose of this article is to review indications, contraindications, advantages, and disadvantages of the basic concepts of RPRPD. This part reviews the philosophy of the basic concept, working from analog to a digital workflow. Two clinical cases for RPRPD are described in detail.

PMID 43053639
阅读全文 →
PubMedBMC gastroenterology2026-11-19

Systemic inflammatory dysregulation and short-term mortality in critically ill patients with sepsis and cirrhosis: incremental prognostic value of the aggregate index of systemic inflammation.

Wang Yulan Y, Yang Song S, Zhang Xinyuan X, Chen Guangmei G

Critically ill patients with sepsis and cirrhosis represent a high-risk population characterized by profound immune-inflammatory dysregulation, coagulation abnormalities, and poor short-term outcomes. The aggregate index of systemic inflammation (AISI), which integrates neutrophil, monocyte, lymphocyte, and platelet counts, may provide a comprehensive assessment of host inflammatory and immune status. However, its prognostic significance in this population remains unclear. This study evaluated the association of AISI with short-term mortality and its additional value for clinical risk stratification in critically ill patients with sepsis and cirrhosis. This retrospective multicohort study included critically ill patients with sepsis and cirrhosis from the MIMIC-IV database (development cohort) and the eICU Collaborative Research Database (independent replication cohort). The primary exposure was natural logarithm-transformed AISI (Ln AISI), analysed as both quartiles and continuously. The primary outcomes were 28-day and 90-day all-cause mortality. In eICU, outcomes were deaths recorded during hospitalisation within the respective follow-up windows; live discharges were censored at hospital discharge. Kaplan-Meier analysis, multivariable Cox proportional-hazards models, restricted cubic splines, propensity-score matching, and prediction analyses were used. A total of 822 patients from MIMIC-IV and 374 patients from eICU were included. Higher Ln AISI levels were associated with higher 28-day and 90-day mortality in both cohorts, with significant dose-response relationships across quartiles (all P for trend < 0.001). Kaplan-Meier analyses showed lower survival probabilities in higher Ln AISI quartiles. These associations remained directionally consistent after propensity score matching. Adding Ln AISI produced limited discrimination gains but improved risk-reclassification metrics and decision-curve net benefit. These findings indicate complementary prognostic information rather than evidence of immediate clinical utility. Elevated AISI was associated with increased short-term mortality in critically ill patients with sepsis and cirrhosis. AISI may provide complementary prognostic information when interpreted alongside established clinical predictors. Its incremental discrimination was limited, and prospective studies are needed before AISI can inform clinical decision-making.

PMID 43052742
阅读全文 →
PubMedBMC cardiovascular disorders2026-11-19

Machine learning insights on stress hyperglycemia ratio and mortality in congestive heart failure patients with cerebrovascular disease: an analysis of the MIMIC-IV database.

Sun Ling L, Ji Ruijing R, Wang Yingjie Y, Wang Tao T et al.

The stress hyperglycemia ratio (SHR), calculated as Admission Blood Glucose (aBG) / (28.7 × glycated hemoglobin A1c (HbA1c) %) - 46.7, integrates acute and chronic glycemic status and predicts adverse cardiovascular events, yet its prognostic value remains unclear among CHF patients complicated with cerebrovascular disease (CVD). This study aimed to explore the association between SHR and all-cause mortality in this specific Intensive Care Unit (ICU) population and provide evidence for targeted glycemic management. We conducted a retrospective cohort study utilizing the MIMIC-IV database. Among 11,196 ICU patients admitted for CHF between 2008 and 2019, 10,214 patients were excluded due to missing HbA1c or admission blood glucose data, resulting in a final analytical cohort of 982 patients. Restricted cubic splines (RCS) and Kaplan-Meier (K-M) curves were employed to illustrate the dose - response association between the SHR and all-cause mortality. Stratified multivariable Cox regression was utilized to estimate hazard ratios, stratified by cerebrovascular disease status. Multiple machine learning models were developed to predict 30-day all-cause mortality, with CatBoost demonstrating the optimal predictive performance. Log-odds-scale SHapley Additive exPlanations (SHAP) values were calculated to quantify the prognostic impact of each variable. A total of 982 CHF patients were enrolled, including 320 with concomitant CVD. RCS revealed a linear positive dose-response association between SHR and 30-day and 365-day all-cause mortality among CHF patients with CVD. K-M curves demonstrated that higher SHR quartiles were associated with worse 30-day and 365-day survival among patients with CVD. After full covariate adjustment, patients in the highest SHR quartile showed significantly elevated 30-day mortality risk [HR = 2.79, 95% CI 1.21-6.42, P = 0.016], with a significant linear trend across SHR quartiles (P for trend = 0.004). Consistently, the highest SHR quartile predicted higher 365-day mortality risk [HR = 2.02, 95% CI 1.12-3.66, P = 0.02], accompanied by an overall positive linear trend [P for trend  = 0.014]. No independent prognostic effect of SHR was observed in patients without CVD. SHAP analysis confirmed SHR as a key predictor for short-term all-cause mortality, and the optimal CatBoost model achieved moderate discriminative performance (AUC = 0.77). Elevated SHR was independently associated with higher 30-day and 365-day all-cause mortality risk solely in critically ill CHF patients with concomitant CVD. The SHR index enables risk stratification and personalized glycemic management for this high-risk ICU cohort.

PMID 43052787
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多indometacin (IV)